Personalized medicine for kidney transplant recipients
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a personalized approach to managing immunosuppression after a kidney transplant to improve long-term kidney function. It may help find the right dose of tacrolimus for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have end-stage renal disease and are receiving a deceased donor kidney transplant.
- You are planning to take tacrolimus as your main anti-rejection medicine.
- You have not received more than one previous kidney transplant.
- You are willing to follow up with the transplant center for up to 15 months after your transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This study looks at the genes of people who have had or will have a kidney transplant. It aims to learn how genetic information might help improve transplant care over time. Participants will give blood, urine, stool, and possibly kidney tissue samples for research.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This study looks at giving anti-infection medications (antibiotics) in a more personalized way soon after a kidney transplant. By carefully adjusting the dose, doctors hope to prevent infections while keeping the new kidney safe.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.